CD38 and plasma cell myeloma: Initial functional proof-of-concept studies performed with chimeric #5-CD38-IgG1 antibody generated from a novel CD38 binding scFv phage antibody demonstrated high affinity binding and cytotoxic activity comparable to daratumumab and isatuximab against myeloma cells.